Difference between revisions of "Template:Estrogen dosages for prostate cancer"
Jump to navigation
Jump to search
Template documentation
imported>Trappist the monk m (cite repair;) |
(Add inline Template:Documentation; wrap references into it) |
||
| Line 51: | Line 51: | ||
|}<!-- | |}<!-- | ||
| − | --><noinclude> | + | --><noinclude>{{Documentation|content= |
==See also== | ==See also== | ||
* [[Template:Estrogen dosages for menopausal hormone therapy]] | * [[Template:Estrogen dosages for menopausal hormone therapy]] | ||
| Line 58: | Line 58: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
| + | }} | ||
[[Category:Medication templates]] | [[Category:Medication templates]] | ||
[[Category:Templates that generate named references]] | [[Category:Templates that generate named references]] | ||
</noinclude> | </noinclude> | ||
Revision as of 16:44, 29 March 2019
| Route/form | Estrogen | Cancer | Dosage | Ref(s) |
|---|---|---|---|---|
| Oral | Template:No selflink | Breast | 6–30 mg/day | [1] |
| Template:No selflink | Breast | 10 mg 3x/day | [2] | |
| Prostate | 1.25–2.5 mg 3x/day | [2][3] | ||
| Template:No selflink | Breast | 1–3 mg/day | [2][1] | |
| Prostate | 0.15–2 mg/day | [2][3] | ||
| Template:No selflink | Prostate | 1–2 mg 1x/week | [4][3] | |
| Template:No selflink | Breast | 5 mg 3x/day | [2] | |
| Prostate | 1–3 mg/day | [2] | ||
| Template:No selflink | Prostate | 120–480 mg 1–3x/day | [5][6] | |
| Template:No selflink | Prostate | 12–25 mg/day | [2] | |
| Template:No selflink | Prostate | 140–1400 mg/day | [7] | |
| Transdermal patch | Template:No selflink | Prostate | 2–6x 100 μg/day | [8][9] |
| IM or SC injection | Template:No selflink | Prostate | 1.66 mg 3x/week | [10] |
| Template:No selflink | Prostate | 5 mg/1x week | [10] | |
| Template:No selflink | Prostate | 30 mg 1x/1–2 weeks | [11] | |
| Template:No selflink | Prostate | 100 mg/4 weeks | [12] | |
| Template:No selflink | Breast | 40–80 mg 1x/4 weeks | [13] | |
| Prostate | 160–320 mg/1x 4 weeks | [13][12] | ||
| Template:No selflink | Prostate | 2–4 mg 2–3x/week | [2] | |
| IV injection | Template:No selflink | Prostate | 300–1200 mg 1–7x/week | [5][6] |
| Template:No selflink | Prostate | 240–450 mg/day | [7][14] | |
| Note: Dosages are not necessarily equivalent. | ||||
See also
- Template:Estrogen dosages for menopausal hormone therapy
- Template:Medications and dosages used in hormone therapy for transgender women
References
- ↑ 1.0 1.1 Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (January 2017). "The use of high-dose estrogens for the treatment of breast cancer". Maturitas. 95: 11–23. doi:10.1016/j.maturitas.2016.10.010. PMID 27889048.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1.
- ↑ 3.0 3.1 3.2 Oettel, M (1999). "Estrogens and Antiestrogens in the Male". In Michael Oettel; Ekkehard Schillinger (eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 505–571. doi:10.1007/978-3-642-60107-1_25. ISBN 978-3-642-60107-1. ISSN 0171-2004.
- ↑ Höfling, G.; Heynemann, H. (2014). "Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?" [Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?]. Der Urologe B. 38 (2): 165–170. doi:10.1007/s001310050185. ISSN 0042-1111.
- ↑ 5.0 5.1 Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2104–2105. ISBN 978-0-85369-840-1.
- ↑ 6.0 6.1 Franz von Bruchhausen; Gerd Dannhardt; Siegfried Ebel; August W. Frahm; Eberhard Hackenthal; Ulrike Holzgrabe (2 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O. Springer-Verlag. pp. 301–. ISBN 978-3-642-57994-3.
- ↑ 7.0 7.1 Perry CM, McTavish D (July 1995). "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs Aging. 7 (1): 49–74. doi:10.2165/00002512-199507010-00006. PMID 7579781.
- ↑ Ockrim J, Lalani EN, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nat Clin Pract Oncol. 3 (10): 552–63. doi:10.1038/ncponc0602. PMID 17019433.
- ↑ Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". J. Urol. 169 (5): 1735–7. doi:10.1097/01.ju.0000061024.75334.40. PMID 12686820.
- ↑ 10.0 10.1 "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy ed.). 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN 0095-9561.
- ↑ https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009402s052lbl.pdf
- ↑ 12.0 12.1 Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, Sydes MR, Abel P, Eastwood AJ (February 2008). "Parenteral oestrogen in the treatment of prostate cancer: a systematic review". Br. J. Cancer. 98 (4): 697–707. doi:10.1038/sj.bjc.6604230. PMC 2259178. PMID 18268497.
- ↑ 13.0 13.1 http://pharmanovia.com/product/estradurin/
- ↑ Bergenheim AT, Henriksson R (February 1998). "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clin Pharmacokinet. 34 (2): 163–72. doi:10.2165/00003088-199834020-00004. PMID 9515186.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |